Loading stock data…
NUTX
$133.77-1.63 (-1.20%)
Market OpenUpdated 3:03 PM EDT
Nutex Health Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Nutex Health Inc. in the Healthcare sector is trading at $133.77. Wall Street consensus targets $235.50 (4 analysts), implying a +76.0% move over the next 12 months. The stock is currently 31% below its 52-week high of $193.07, remaining 10.4% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +76.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $216.49M↑ | $151.68M↓ | $267.80M↑ | $243.99M↑ | $211.79M |
| Gross Profit | $91.73M↑ | $46.14M↓ | $154.88M↑ | $124.92M↑ | $118.34M |
| Operating Income | $81.27M↑ | $30.92M↓ | $130.37M↑ | $33.68M↓ | $80.66M |
| Net Income | $46.81M↑ | $11.83M↓ | $55.44M↑ | -$17.70M↓ | $21.22M |
Peer Comparison
JNJUNHPFE
Fundamentals
Nutex Health Inc. operates as a healthcare services and operations company in the United States. It operates through three segments: Hospital, Population Health Management (PHM), and Real Estate. The Hospital segment develops and operates a network o...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
27.83%
Volume
Today's trading volume
163,709
Recent News
3 Undervalued Small Caps With Insider Action Across Regions
The United States market has shown a robust performance, climbing 1.6% in the last week and an impressive 28% over the past year, with earnings projected to grow by 17% annually. In this dynamic environment, identifying stocks that are potentially undervalued can be crucial for investors looking to capitalize on growth opportunities, especially when there is notable insider action signaling confidence in these companies' prospects.
Nutex Health NUTX Q2 2025 Earnings Transcript
For the first half of 2025, total patient visits were 93,842, a 15.5% increase from the first half of 2024. Total revenue increased to $244 million for the three months ended June 30, 2025, as compared to total revenue of $76.1 million for the same period in 2024, an increase of 220%. Gross profit was $124.8 million or 51.1% of total revenue for the three months ended June 30, 2025, as compared to gross profit of $22.6 million or 29.7% of total revenue for the same period of 2024.
Explore These 3 Undervalued Small Caps With Insider Buying Across Regions
Over the last 7 days, the United States market has remained flat, yet it has seen a significant rise of 28% over the past year with earnings expected to grow by 16% annually in the coming years. In this dynamic environment, identifying stocks that are potentially undervalued and exhibit insider buying can be an effective strategy for investors looking to capitalize on growth opportunities within small-cap companies.
Nutex Health And 2 Other Undiscovered Gems In The US Market
Over the last 7 days, the United States market has remained flat, yet it is up 28% over the past year with expectations for earnings to grow by 16% per annum in the coming years. In this dynamic environment, identifying undiscovered gems like Nutex Health can offer unique opportunities for investors seeking to uncover stocks with potential growth that align well with current market conditions.
A Look At Nutex Health (NUTX) Valuation After Strong Q1 2026 Results And New Buyback Program
Nutex Health (NUTX) stock is in focus after first quarter 2026 earnings, where revenue reached US$216.5 million and net income rose to US$46.8 million, with diluted EPS at US$6.52. See our latest analysis for Nutex Health. Following the earnings release and plans for three new hospitals plus a fresh repurchase program, Nutex Health’s 1 day share price return of 17.1% and 7 day share price return of 28.9% suggest short term momentum is picking up. However, the 90 day share price return of...